Some intrinsic subtypes of breast cancer are associated with elevated susceptibility to specific drugs, such as Herceptin (for amplified HER2 cases) and Tamoxifen (for ER+ cases), while other subtypes, such as the mesenchymal basal/triple negative cases remain without a matching therapeutic strategy. Here, ESR1 is linked to breast cancer.